Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.8%

41 terminated/withdrawn out of 529 trials

Success Rate

83.7%

-2.9% vs industry average

Late-Stage Pipeline

16%

86 trials in Phase 3/4

Results Transparency

10%

20 of 210 completed trials have results

Key Signals

100 recruiting20 with results31 terminated10 withdrawn

Enrollment Performance

Analytics

N/A
243(59.1%)
Phase 2
56(13.6%)
Phase 4
47(11.4%)
Phase 3
39(9.5%)
Phase 1
21(5.1%)
Early Phase 1
5(1.2%)
411Total
N/A(243)
Phase 2(56)
Phase 4(47)
Phase 3(39)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (532)

Showing 20 of 532 trials
NCT07739823Not Yet Recruiting

Validation of a Wireless Wearable Vital Signs Monitor in Pediatric Patient

Role: lead

NCT07739784Recruiting

This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.

Role: lead

NCT07739810Not Yet Recruiting

Miniaturized Vital Sign Monitoring for Newborns in the Delivery Room

Role: lead

NCT07732452Phase 4Not Yet Recruiting

Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition

Role: lead

NCT07732257Not ApplicableRecruiting

Wireless MicroPremVitals Button Sensor in the NICU

Role: lead

NCT07732244Not ApplicableRecruiting

Evaluating a Wireless NIRS Device in the Neonatal Intensive Care Unit

Role: lead

NCT06614959Not ApplicableCompleted

The Effects of Oscillatory Positive Expiratory Pressure (OPEP) Therapy in Patients With COPD

Role: lead

NCT04818138Not ApplicableTerminated

BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort

Role: collaborator

NCT05592938Not ApplicableRecruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Role: collaborator

NCT05309785Phase 4Completed

Safety and Efficacy of Canagliflozin in Advanced CKD

Role: lead

NCT07625930Phase 2Not Yet Recruiting

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

Role: lead

NCT07249827Phase 2Completed

A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block

Role: lead

NCT07374952Phase 4Recruiting

Minimal Effective Volume 90% for Double-injection Costoclavicular Block

Role: lead

NCT06335264Completed

Screening for Heart Failure Using a Multimodal Wearable Device

Role: lead

NCT06979609Phase 2Recruiting

Secondary Prevention of Clostridioides Difficile Using Vancomycin

Role: lead

NCT07328971Phase 3Recruiting

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

Role: lead

NCT07659106Not ApplicableNot Yet Recruiting

Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism

Role: lead

NCT07655076Early Phase 1Recruiting

Simultaneous Measurement and Responsive Treatment - Part 2

Role: collaborator

NCT04272307Early Phase 1Completed

MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.

Role: collaborator

NCT07639541Not ApplicableNot Yet Recruiting

Radio-frequency (RF) Bladder Monitor

Role: lead